Human Beta Cell Line Generation via Lentiviral Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating functional human Beta cell lines in large quantities for diabetes treatment and diagnosis are inefficient, with previous approaches failing to produce mature, insulin-secreting cells on a commercial scale, and existing cell lines are not amenable for human application due to low efficiency and restricted applicability.
Innovation Solution
A method involving transduction of immature human pancreases with lentiviral vectors expressing SV40 LargeT antigen and hTERT under the insulin promoter, followed by sub-grafting and enrichment steps to generate and amplify human Beta cell lines that can be transplanted to normalize blood glucose levels in diabetic mice and used for diabetes diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If adult Beta cells are transformed using x-ray induced rat insulinoma or SV40 transformation, then human Beta cell lines can be generated, but the efficiency is extremely low with only one human Beta cell line developed among 253 clones analyzed
Solution Approach 1:
The patent changes the starting material from adult Beta cells to immature human pancreas tissue, and modifies the transformation approach by using lentiviral vectors expressing SV40 LargeT antigen and hTERT under the control of the insulin promoter. This parameter change enables efficient generation of functional human Beta cell lines that can be expanded in culture, directly resolving the low efficiency problem of previous methods
Solution Approach 2:
The patent performs preliminary action by infecting immature human pancreas tissue with lentiviral vectors before transplantation. This pre-infection step ensures that the Beta cells developing from the immature tissue already carry the immortalization genes, enabling subsequent efficient expansion and line establishment without the low efficiency associated with transforming differentiated adult cells
2Quantity of substance
If ES cells are used as starting material to produce mouse or human Beta cells, then Beta cells can be generated in large quantities, but reproducible protocols were not yet available and functional Beta cells were not generated in large quantities
Solution Approach 1:
The patent uses immature human pancreas tissue as a starting material that can be copied and transplanted multiple times. Each transplantation event serves as a replication of the infection and differentiation process, enabling scalable production of functional Beta cells with consistent results, thus providing a reproducible protocol for large-scale generation
Solution Approach 2:
The patent introduces lentiviral vectors as an intermediary that delivers immortalization genes (SV40 LargeT antigen and hTERT) specifically to Beta cell precursors in immature pancreas. This intermediary approach enables controlled transformation and efficient generation of expandable Beta cell lines, establishing a reproducible protocol for large-scale production
3Reliability
If transgenic mice expressing SV40 T antigen under the control of the insulin promoter are used, then Beta cell lines can be derived, but the application is restricted to animal models without any possible transfer to human
Solution Approach 1:
Instead of using transgenic animal models and attempting to translate to human, the patent inverts the approach by directly applying the same lentiviral infection strategy to human immature pancreas tissue. This inversion eliminates the animal model restriction and directly produces human Beta cell lines applicable to human diabetes treatment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method successfully generates 11 independent human Beta cell lines that express insulin and have a gene expression profile similar to adult Beta cells, capable of normalizing glycemia in diabetic mice and detecting autoantibodies, paving the way for clinical use in diabetes treatment and diagnosis.
Implementation Method 1
transduction of immature human pancreases with lentiviral vectors expressing SV40 LargeT antigen and hTERT under the insulin promoter
Implementation Method 2
capable of normalizing glycemia in diabetic mice and detecting autoantibodies
Data Source
AI summary
The present invention relates to a method for preparing commercial scale quantities of human functional Betacells and to the establishment of cell lines. It also relates to a method of diagnosis using Beta cell tumors or cells derived thereof. The method comprises sub-transplantation procedure to enrich the graft in proliferating Betacells, allowing to generate human Betacell lines. Such lines express little amount of insulin and have a gene expression profile that resembles to adult Betacells. In addition, the human Betacell lines are able to normalize glycemia of diabetic mice when transplanted, demonstrating their insulin secretion capabilities.